The Expressions Of COX-2and P53in Prostate Carcinoma And Its Clinical Significance

Background:Prostate cancer is a high incidence in older men。 Prostate cancer in Europe andthe United States accounted for the first of the malignant tumors in the male reproductivesystem, the mortality rate ranked second, second only to lung cancer. Recent incidenceof Prostate cancer in China is increasing rapidly. Men are currently diagnosed at anearly stage In many cases, prostate cancer can be surgery or radiation therapy. However,the one-third of patients, the disease will relapse, and ultimately develop into Hormonerefractory prostate cancer and metastatic prostate cancer. As a new treatment for cancergene therapy is considered to be increasing.It is reported that COX-2the height of the epithelium in a variety ofregulatory Malignant tumors such as lung, stomach, colon Cervical cancer and ovariancancer. COX-2has been reported Tumor stage, tumor grade, histological grade andprognosis. Therefore, COX-2may be a potential molecular target of cancer therapyTreatment. P53is an important tumor suppressor gene to prevent cell replication and Themaintenance of genome stability, maintaining normal cell growth and promoteapoptosis Inhibit the proliferation of malignant cells, the growth regulator is a negativeimpact. Its Mutation and inactivation plays an important role in the process of tumorgrowth and Infiltration. This indicates that p53gene mutation may be closely related toa A variety of human tumors. Lung cancer, colon cancer, breast cancer, liver cancer,prostate cancer Cancer, bladder cancer, ovarian cancer,brain tumor, nasopharyngeal carcinoma, The p53gene is highly expressed in the report. P53gene inactivation,indicate that mutations in p53overexpression. Mutant P53protein does not Show onlyloss of the normal tumor suppressor role, but also to promote normal cell Malignanttransformation.Recently, studies have shown that p53and COX-2expression is closely related, yetthe combination of the two studies reported in the literature,The combined detection ofp53and COX-2expression in the prostate cancer, It plays an important role in theundersatanding of process in the development and the diagnosis prognosis of prostatecancer.Objective:By using immunohistochemistry and RT-PCR to detect the expression of COX-2,p53protein in different pathological and clinical staging in prostate cancer tissue andadjacent noncancerous prostate tissue.To discuss the significance of COX-2and p53incarcinogenesis、progression、angiogenesis and their correlations of prostate carcinoma，providing a new approach for the diagnosis and treatment of the tumor.Methods:Firstly，Select between the2004-2009158cases treated by surgery urology patientsin the Guangzhou First Municipal People’s Hospital. The transfer of clinical records andtissue samples, while the establishment of non-tumor tissue adjacent to the tumorcontrol,benign prostate hyperplasia tissue, COX-2immunohistochemistry and RT-PCRdetection, combined with clinical data (age serum PSA level, Gleason score, tumor stage,lymph node metastasis), The statistical analysis was accomplished by SPSS13.0software.Results:Immunohistochemical results showed that COX-2and p53in prostate cancer tissuethan adjacent to the tumor without tumor tissue, benign prostate hyperplasia tissue Highlyexpressed in prostate cancer patients with Gleason score,tumor stage,lymph node metastasis, with statistical significance. COX-2mRNA, p53mRNA expression levels inprostate cancer tissue was significantly higher than the adjacent non-tumor tissue in theprostate carcinoid been verified by RT-PCR to further validate the prostate cancer cellCOX-2mRNA specific expression.Conclusion：Through this research, the COX-2, p53higher expression in prostate cancer, confirmedthe occurrence of COX-2, p53could become a new marker for early diagnosis,judgmentof prognostic and a potential molecular therapeutic target for cancer therapy.. COX-2, p53two kinds of protein expression in PCa tissue, there is a positive combination of detectionfor prostate cancer progression and prognosis prediction to provide a reference value.